NCT05512598

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

Multi-centre, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of HB0034 in Patients Acute Generalized Pustular Psoriasis (GPP) Flare

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HB0034 in adult patients with generalized pustular psoriasis (GPP ).

Detailed description

This is an open-label, multicenter, phase Ib exploratory study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HB0034 in adult patients presenting moderate-severe generalized pustular psoriasis (GPP ) flare.

Conditions

• Generalized Pustular Psoriasis

Interventions

Type	Name	Description
DRUG	HB0034	HB0034, a single dose

Timeline

• Start date: 2022-11-06
• Primary completion: 2023-11-15
• Completion: 2024-01-10
• First posted: 2022-08-23
• Last updated: 2024-01-23

Locations

1 site across 1 country: China